

RESEARCH ARTICLE

Open Access



Prevalence of seropositivity of selected herpesviruses in patients with multiple sclerosis in the North of Jordan

Raid M. Kofahi^{1*} , Hassan M. Kofahi², Suhib Sabaheen², Majdi Al Qawasmeh¹, Aiman Momani¹, Ahmed Yassin¹, Kefah Alhayk¹ and Khalid El-Salem¹

Abstract

Background: Multiple sclerosis (MS) is a neurological disease that is caused by an autoimmune response that results in the neuron's demyelination in the central nervous system. The exact etiology of MS is not clear; however, several environmental and genetic factors are believed to participate in its initiation and development, including exposure to viruses. This study aims to investigate the association between the seropositivity and antibody titer of selected herpesviruses and MS in Jordanian MS patients.

Method: In this study, 55 MS patients and 40 age- and gender-matching apparently healthy volunteers were recruited from two main hospitals in the north of Jordan. MS patients were grouped into three types of MS based on the clinical presentation of the disease. Blood samples were collected from the participants and the IgG antibodies for human herpesvirus 6 (HHV-6), Epstein-Barr virus (EBV) nuclear antigen (EBNA), EBV viral capsid antigen (VCA) and varicella-zoster virus (VZV) were assayed by ELISA. The prevalence of seropositivity and the antibody level for each of the antibodies were compared between MS patients and controls and between the three types of MS.

Results: There was no significant difference in the prevalence of seropositivity and in the levels of antibodies for HHV-6, EBNA and VCA between MS patients and controls and between the three types of MS. In contrast, the number of seropositive patients and the level of IgG antibodies for VZV were significantly higher in MS patients compared to the control.

Conclusion: This study showed that patients with MS in the north of Jordan were more likely to be seropositive for VZV than the general population. Based on this finding, we recommend further studies to evaluate the seropositivity to VZV to be carried out in other parts of Jordan and the greater middle east to find out if there is a correlation between MS and previous infection with VZV.

Keywords: Multiple sclerosis, Autoimmunity, Varicella, Jordan, Middle East

* Correspondence: rmkofahi@just.edu.jo

¹Department of Neurosciences, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Multiple sclerosis (MS) is one of the most prevalent neurological diseases affecting approximately 2.1 million patients worldwide [1]. It is, widely, believed that MS is caused by an autoimmune response that affects the myelin sheath in the central nervous system, which subsequently results in the demyelination of nerve cells in the brain and the spinal cord [2]. The course of disease varies largely among MS patients, and can be presented as one of three clinical types [3, 4]. Most of the patients experience a relapsing-remitting MS (RRMS) pattern, which is characterized by periods of disease activity and symptoms that are followed by periods of partial or complete recovery [3, 5]. The disease may transform into secondary progressive MS (SPMS) over a period of about 20 years in about 70% of RRMS patient. The transformation into SPMS can occur at a rate of 2–3% per year [6]. SPMS is, currently, considered as the second phase of the disease. During this phase of the disease, patients continue to experience worsening of disease symptoms, without periods of remission [7]. Finally, approximately 10–15% of MS patients experience the primary progressive form of MS (PPMS), which is characterized by an unremitting reduction in neurological functioning that is not preceded by episodic relapses [8].

Similar to most of other autoimmune diseases, the exact etiology of MS is not fully understood. However, it is strongly believed that multiple genetic and environmental factors play a role in the initiation and progression of the disease. Exposure to viruses is thought to be a potential environmental factor. Viral infections had been linked to increased risk of the development of different autoimmune diseases. For example, it has been reported that enterovirus and cytomegalovirus (CMV) increase the risk of type 1 diabetes [9–13]. Infections with Epstein-Bar virus (EBV) and CMV increase the risk of systemic lupus erythematosus (SLE) [14–16]. Consequently, the association between viral infections and the development and progression of MS was investigated by several research groups in different geographical areas. These groups reported associations between MS and infections with several viruses, including EBV, CMV, and human herpesvirus 6 (HHV6) [17–19].

Herpesviridae is a family of enveloped, double-stranded DNA viruses, which is divided into three subfamilies; alpha, beta and gamma [20]. However, only a few of these viruses can infect humans. After an initial infection with a herpesvirus, the virus enters a latency phase in which the it remains dormant for an extended period of time. Reactivation of the virus later in life causes a recurrence in disease (reviewed in [21]). Human Herpesvirus 6 (HHV-6) is a member of the β -herpesviruses subfamily. HHV-6 was first isolated in 1986 from patients with AIDS and immunoproliferative

syndrome, and was initially referred to as human B-lymphotropic virus (HBLV) [22]. However, subsequent studies revealed that this virus was actually able to infect a wide variety of organs including salivary glands, epithelial cells, T cells, and macrophages [23]. Epstein-Barr virus (EBV) is a member of the γ -herpesviruses subfamily that is able to infected B cells and epithelial cells [24]. EBV was first isolated in 1964 from a Burkitt's lymphoma cell line [25]. EBV is now known to cause infectious mononucleosis and other diseases. Varicella-zoster virus (VZV) is classified as a member of alpha Herpesviruse subfamily. Primary infection with VZV causes varicella (chickenpox), after which the virus undergoes a state of latency in the dorsal ganglia [26]. Reactivation of the virus later in life causes a more severe disease called shingles [26].

Several previous studies reported that exposure to Herpesviruses may act as a trigger for the development of MS [27–32]. Despite these reports, the role of different viral infections and viral reactivation in MS development is still highly controversial. The reason for this controversy could be attributed in part to discrepancies between the results of published studies, which are probably confounded by variations in genetic and environmental factors between the different geographical locations in which the studies were conducted. It was this discrepancy that prompted us to investigate whether the infection and reactivation of Herpesviruses could be associated with the development and progression of MS in the Jordanian population. Such information could be particularly important in light of the fact that the association was not studied previously in Jordan. Identifying this association would be of great importance to understanding the risk factors for the development and progression of MS in Jordan, where etiological studies are scarce. It can also help predict the disease's possible outcomes and select the best treatment options for the Jordanian MS patients.

Methods

Study sample

The study population was defined as all visitors of the outpatient clinics at King Abdullah University Hospital and Princess Basma Teaching Hospital in the period between July/2017 and November/2017. Ninety-five participants (55 MS patients, and 40 apparently healthy controls) were enrolled in the study. Ages for study participants ranged between 19 and 63 years. The study was approved by the institutional review board (IRB) at King Abdullah University Hospital and was also approved by the Jordanian Ministry of Health. All the participants signed an informed written consent before participating in the study. Participants in the study were matched on two factors; gender and age. The percent of male and

female participants were closely matched between the control and the patient groups. In addition, the age range of 19–63 years that was defined in the inclusion criteria for this study was stratified into groups of 5-year periods, where a similar percentage of participants had to enroll in both groups within the different strata.

Patients' information (age, gender and type of MS) were collected by using a questionnaire form that was developed by us for this study (see supplementary file 1) and by consulting their medical records. Patients were divided into three groups based on the type of MS. These groups are: RRMS, SPMS and PPMS. There were no exclusion criteria in this study in terms of age, sex, race or geographical residence. Gender- and age-matching healthy control group was recruited and used for comparison purposes.

Blood sample collection and processing

For each participant, an approximately 4 ml blood sample was collected in a plain tube and was transported immediately to the research laboratory in the faculty of Applied Medical Sciences – Department of Medical Laboratory Sciences at Jordan University of Science and Technology (JUST). Blood samples were centrifuged upon arrival then serum was separated. Each serum sample was divided into aliquots into at least four small tubes and immediately stored at -20°C until the day of analysis.

Measurement of antibody titers

HHV-6 IgG antibody was assayed by using a commercially available semi-quantitative ELISA kit (Vidia, Czech Republic). The protocol recommended by the manufacturer was followed. Index values for HHV-6 IgG were calculated by using the following formula: Index = the mean optical density (OD) value for the sample/cut-off value. In the qualitative analysis, index values above 1.1 were considered positive.

The IgG antibodies for Epstein Barr nuclear antigen (EBNA), EBV viral capsid antigen (VCA) and VZV were measured by commercially available quantitative enzyme-linked immunosorbent assay (ELISA) kits (IBL, Germany) according to the manufacturer's recommended protocol.

Any sample with antibody level above 12 U/ml was considered positive in the qualitative analysis.

Statistical analysis

Data analysis was performed by Graph Prizm 7 software. Descriptive statistics were used to summarize patients' demographics. Chi-square and two-tailed t-test were used to test for statistical differences between the patients' group and the control group, and then between the three subgroups of MS. Analysis of variance (ANOVA) was used to test the antibody level differences between the three groups of MS patients. *P*-values of less than 0.05 were considered significant.

Results

Study population

A total of 55 MS patients and 40 controls were enrolled in the study. The two groups were matched in the percent of male-to-female ratio ($P = 0.763$). The control group consisted of 15 (37.5%) males and 25 (62.5%) females, while in the patients' group, there were 20 (36.4%) males and 36 (62.5%) females (see Table 1). The difference in the enrolment among the two genders can be explained by the higher prevalence of MS among females than males. The control group's mean age was 35.5 ± 10.8 years, and 36.2 ± 11.2 years for the MS group. There was no statistically significant difference in the mean ages between the patients and control groups ($p = 0.7630$) (Table 1).

MS Patients were assigned to one of three groups, depending on the clinical course of the disease. The groups were (i) relapsing-remitting (RRMS) (30; 55.6%), (ii) secondary progressive (SPMS) (20; 36.4%), and (iii) primary progressive (PPMS) (5, 9.1%). See Table 1. That is consistent with the literature, which indicates that about up to 85% of MS patient follow the RRMS course, and that more than half of those patients eventually develop SPMS, and that less than 10% of MS patients have a disease that is progressive from the onset (or PPMS) [33].

HHV-6 antibody in MS patients

HHV-6 IgG antibody levels were measured for each all patients and controls, and an index value for each

Table 1 Demographic characteristics of the study population

	Control	Patients	<i>p</i>
Number	40	55	
Age	36.2 ± 11.2	35.5 ± 10.8	0.763 (t test)
Gender	15 Males (37.5%) 25 Females (62.5%)	20 Males (36.4%) 35 Females (63.6%)	0.9097 (Chi square test)
Type		30 RR (54.6%) 20 SP (36.4%) 5 PP (9.1%)	

Note: Age is presented as mean \pm SEM




Fig. 1 HHV-6 IgG levels: **a** shows a comparison in the levels of HHV-6 IgG between control and patients groups. **b** Shows a comparison in the HHV-6 IgG levels between the three types of MS (RRMS, SPMS and PPMS). The data is presented as the mean HHV6-IgG level \pm SD

enrollee was calculated. Index values > 1.1 were considered positive (as per the instructions of the kit manufacturing company). There was no significant difference between patients and controls (86% of patients and 85% of controls were seropositive ($p = 0.951$)). The mean index value for HHV-6 IgG antibody for the patients' group was 2.171 ± 0.1485 , which was slightly lower than that for the control group, which was 2.35 ± 0.198 . However, the difference was not statistically significant ($p = 0.4636$) (Fig. 1a). Furthermore, there was no significant difference in HHV-6 IgG levels between the three types of MS ($p = 0.1102$). The mean index values were 2.446 ± 0.2098 , 1.897 ± 0.2261 and 1.614 ± 0.3472 for RRMS, SPMS and PPMS, respectively (Fig. 1b).

EBV antibodies in MS patients

Two EBV antibodies were measured; viral capsid antigen (VCA) IgG and EBV nuclear antigen-1 (EBNA) IgG in patients and controls using ELISA. Both antibodies, typically appear during or after the acute phase of infection and remain elevated for life. There was statistically insignificant difference in the prevalence of EBV antibodies between MS patients and controls ($p = 0.755$). As indicated in Table 2, The vast majority of patients (96%) and

controls (98%) show evidence of previous exposure to EBV and tested positive for either VCA IgG, EBNA-1 IgG, or both.

As shown in Fig. 2, the mean for VCA levels were 214.2 ± 16.99 U/ml and 196.7 ± 15.77 U/ml for the patients and control groups, respectively. There was no statistically significant difference in VCA IgG level between the two groups ($p = 0.47$). The mean VCA levels in each type of MS were 245.9 ± 20.68 U/ml, 180.4 ± 28.66 U/ml and 159.1 ± 72.37 U/ml for the RRMS, SPMS and PPMS, respectively. Comparison of VCA IgG levels between the three types of MS did not show any statistically significant difference ($p = 0.1160$, one-way ANOVA test).

Similarly, there was no statistically significant difference in the EBNA1 IgG levels between patients' and control group ($p = 0.4861$). The mean EBNA1 levels were 25.54 ± 2.322 U/ml and 28.3 ± 3.352 U/ml for the patients and control groups, respectively (Fig. 2 c). Finally, there was no statically significant difference in EBNA1 IgG levels between the three types of MS ($p = 0.6878$). The mean EBNA1 IgG levels for RRMS, SPMS and PPMS were 26.94 ± 3.48 U/ml, 24.85 ± 3.401 U/ml and 19.88 ± 6.527 U/ml respectively (Fig. 2).

Table 2 Prevalence of HHV-6, EBV and VZV IgG antibodies in the study populations. $p < 0.05$ is considered significant (Chi square test)

	Patients No. (%) of seropositive	Controls No. (%) of seropositive	<i>p</i>
HHV-6 IgG	47 (86%)	34 (85%)	0.951
EBV IgG			
VCA IgG	50 (91%)	37 (93%)	0.783
EBNA-1 IgG	41 (75%)	31 (78%)	0.740
VCA IgG, EBNA-1 IgG or both	53 (96%)	39 (98%)	0.755
VZV IgG	54 (98%)	31 (78%)	0.001




Fig. 2 EBV antibody levels in MS patients: **a** VCA IgG antibody level in MS patients compared to control. **b** VCA IgG antibody levels in RRMS, SPMS and PPMS. **c** EBNA1 IgG antibody level in MS patients compared to control. **d** EBNA1 IgG antibody levels in RRMS, SPMS and PPMS. Data is presented as mean ± SD

VZV antibody levels in MS patients

Finally, we also analyzed the prevalence and levels of VZV IgG antibody in MS patients. About 98% of patients tested positive for VZV IgG, which was significantly higher than the prevalence of VZV IgG (78%) in the controls ($p = 0.001$) (Table 2). By comparing the levels of VZV IgG between MS patients and controls, we found a significantly higher mean level of VZV IgG in

MS patients (103.2 ± 9.052 U/ml) than the control (68.58 ± 10.73 U/ml) ($p = 0.0152$) (Fig. 3a). However, the levels of VZV IgG antibodies between the three types of MS did not show a statistically significant difference ($p = 0.9177$, one-way ANOVA test). The VZV IgG levels were 101.6 ± 10.6 U/ml, 107.7 ± 18.23 U/ml and 95.19 ± 30.35 U/ml for RRMS, SPMS and PPMS, respectively (Fig. 3b).




Fig. 3 VZV antibody levels in MS patients: **a** VZV IgG antibody level in MS patients compared to control. **b** VZV IgG antibody levels in RRMS, SPMS and PPMS. Data is presented as mean ± SD

Discussion

Understanding the etiology and pathogenesis of MS has been the focus of several research groups. Despite the extensive research, the exact etiology of MS remains ambiguous. However, nowadays, it is mainly acceptable that multiple genetic and environmental factors participate in the initiation and progression of the disease [34, 35]. Many considered exposure to viruses as one of the major etiologic environmental factors for MS [35]. This study is the first exploratory study to investigate the associated between viral exposure or reactivation and MS in the Jordanian population. The sample size was limited by the recent establishment of the local registry and availability of electronic medical records for MS patient in the north of Jordan. Future studies will be more likely to include larger number of patients as electronic medical records have become more readily available on a larger number of MS patients.

In this study, we investigated the exposure of Jordanian MS patients to three important viruses of the *Herpesviridae* family; HHV-6, EBV and VZV, by measuring serum levels of IgG antibodies to each of these viruses. Our results showed a higher prevalence and levels of VZV IgG antibody in MS patients compared to controls. This result is in agreement with previous reports from other geographical areas in which higher prevalence of VZV virus infection was also reported [36–40]. One published study was done in a middle eastern country by Aramideh Khouy et al. had also showed that the prevalence of VZV IgG antibodies was higher in MS patients than controls [41]. These results suggest a possible role of VZV infection in the etiology and/or pathogenesis of MS. The implication of VZV in MS is supported further by other studies in which VZV DNA was detected in the CSF and in the peripheral mononuclear cells of most MS patients during the relapse, but only in few of the patients during remission [42–45]. Furthermore, VZV-like viral particles were visualized by electron microscopy in the CSF of MS patients during relapse and these viral particles were infective to Vero E6 cells in vitro [45–47].

Primary infection with VZV causes varicella (chickenpox), after which the virus undergoes latency in the ganglia of peripheral somatic, autonomic, and enteric neurons [48]. Reactivation of the virus later in life causes a more serious disease known as zoster (shingles). The mechanism by which VZV infection participates in the development of MS is not clear [49]. Generally, several mechanisms of pathogen-induced autoimmunity were proposed including molecular mimicry, epitope spreading and bystander activation (reviewed in [49]). Molecular mimicry between viral and self-antigens may trigger a damaging autoimmune response against the myelin. In support of this hypothesis, glycoprotein E (gE) of VZV

was reported to share more than 62% of the amino acid sequence with PrLD/M9 epitopes of the RNA-binding protein HNRNPA1 [50]. Due to this mimicry, antibodies and T-cell responses against viral gE may cross-react with HNRNPA1 proteins in the neurons leading to autoimmune responses against them.

The EBNA1 IgG levels were higher in the control groups than in the patients' group. However, the difference was not statistically significant. In addition, the prevalence and HHV-6 antibody level between MS patients and controls was not statistically significant. These results must be interpreted with caution as they are in conflict with multiple reports from other countries [51–53]. The absence of association between MS and EBV seropositivity in our study could be attributed to the extremely high seropositivity rate in the normal control population (98%). This high prevalence is in agreement with other reports in the Middle East region [54, 55]. Such a high prevalence in normal control could mask any difference seen in MS patients. To overcome this, future studies should be conducted in Jordan with a much higher sample size.

Conclusion

In summary, our study demonstrated statistically significant higher levels of VZV IgG in patients with MS compared to the control group in the north of Jordan which reflects the general population of Jordan, which is largely understudied. This finding may indicate that the previous infection with VZV may play a role in the etiology or the pathogenesis of MS in this population. Further studies are needed on the population of Jordan and the greater middle east in larger Cohorts to evaluate further the prevalence of the previous infection with VZV in patients with MS.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12883-020-01977-w>.

Additional file 1.

Abbreviations

MS: Multiple Sclerosis; EBV: Epstein-Barr Virus; HHV-6: Human herpesvirus 6; VZV: Varicella-Zoster Virus; CMV: Cytomegalovirus; CNS: Central Nervous System; RRMS: Relapsing-Remitting Multiple Sclerosis; SPMS: Secondary Progressive Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis; IgG: Immunoglobulin G; ELISA: Enzyme-linked Immunosorbent Assay; EBNA: Epstein-Barr nuclear antigen; VCA: Viral capsid antigen; SLE: Systemic lupus erythematosus; IRB: Institutional review board

Acknowledgements

Not applicable.

Authors' contributions

R.K: Conceptualization; Data curation; Funding acquisition; Investigation; Methodology; Project administration; Supervision; Validation; Writing - original draft; Writing - review & editing of final draft. H.K: Conceptualization;

Funding acquisition, Data curation; Formal analysis; Investigation; Methodology; Resources; Validation; Writing - original draft. S.S: Data collection. Investigation, Collecting blood samples. M.Q: Supervision; Writing - review & editing. A.M: Data collection; Writing: review and editing. A.Y: Data collection; Writing - review & editing. K.A: Data collection; Writing - review & editing. K.E: Conceptualization; Supervision; Writing: review & editing of final draft. The author(s) read and approved the final manuscript.

Authors' information

Raid M. Kofahi. Assistant professor at Jordan University of Science and Technology.

Board certified in Neurology by Jordanian Medical Council.

Board certified in Neurology, Clinical Neurophysiology and Sleep Medicine by the American Board of Psychiatry and Neurology.

Funding

This study was funded by the department of scientific research at the Jordan University of Science and Technology. Funding covered laboratory testing, kit purchasing, and paid research assistant whose work included interviewing patients and collecting samples.

Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the institutional review board (IRB) at King Abdullah University Hospital and was also approved by the Jordanian Ministry of Health. All the participants signed an informed written consent before participating in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Neurosciences, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan. ²Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, Jordan.

Received: 2 May 2020 Accepted: 23 October 2020

Published online: 29 October 2020

References

- Zwibel HL, Smrta J. Improving quality of life in multiple sclerosis: an unmet need. *Am J Manag Care*. 2011;17(Suppl 5 Improving):S139–45.
- Goverman J. Autoimmune T cell responses in the central nervous system. *Nat Rev Immunol*. 2009;9(6):393–407.
- Fitzner D, Simons M. Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. *Curr Neuropharmacol*. 2010;8(3):305–15.
- Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. *Neurology*. 1996;46(4):907–11.
- Lublin FD, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014;83(3):278–86.
- Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. *Curr Opin Neurol*. 2007;20(3):269–74.
- Koch M, et al. The natural history of secondary progressive multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2010;81(9):1039–43.
- Miller DH, Leary SM. Primary-progressive multiple sclerosis. *Lancet Neurol*. 2007;6(10):903–12.
- Brodacki B, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. *Neurosci Lett*. 2008;441(2):158–62.
- Lietzen N, et al. Enterovirus-associated changes in blood transcriptomic profiles of children with genetic susceptibility to type 1 diabetes. *Diabetologia*. 2018;61(2):381–8.
- Aarnisalo J, et al. Cytomegalovirus infection in early infancy: risk of induction and progression of autoimmunity associated with type 1 diabetes. *Diabetologia*. 2008;51(5):769–72.
- Zanone MM, et al. Association of cytomegalovirus infections with recurrence of humoral and cellular autoimmunity to islet autoantigens and of type 1 diabetes in a pancreas transplanted patient. *Transpl Int*. 2010;23(3):333–7.
- Yoneda S, et al. A histological study of fulminant type 1 diabetes mellitus related to human Cytomegalovirus reactivation. *J Clin Endocrinol Metab*. 2017;102(7):2394–400.
- Perez-Mercado AE, Vila-Perez S. Cytomegalovirus as a trigger for systemic lupus erythematosus. *J Clin Rheumatol*. 2010;16(7):335–7.
- Gross AJ, et al. EBV and systemic lupus erythematosus: a new perspective. *J Immunol*. 2005;174(11):6599–607.
- Larsen M, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. *PLoS Pathog*. 2011;7(10):e1002328.
- Pormohammad A, et al. Relationship of human herpes virus 6 and multiple sclerosis: a systematic review and meta-analysis. *J Cell Physiol*. 2018;233(4):2850–62.
- Langer-Gould A, et al. Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: a multiethnic study. *Neurology*. 2017;89(13):1330–7.
- Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis: an update. *Curr Opin Virol*. 2014;9:127–33.
- De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. *Clin Microbiol Rev*. 2005;18(1):217–45.
- Grinde B. Herpesviruses: latency and reactivation - viral strategies and host response. *J Oral Microbiol*. 2013;5.
- Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, Halligan G, Biberfeld P, Wong-Staal F, Kramarsky B, Gallo RC. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. *Science*. 1986;234(4776):596–601. <https://doi.org/10.1126/science.2876520>.
- Lusso P, et al. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). *J Exp Med*. 1988;167(5):1659–70.
- Shannon-Lowe C, et al. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. *J Virol*. 2009;83(15):7749–60.
- Epstein A. Why and how Epstein-Barr virus was discovered 50 years ago. *Curr Top Microbiol Immunol*. 2015;390(Pt 1):3–15.
- Ayoade F, and W.G. Gossman, Varicella (Chickenpox), Zoster, in *StatPearls*. 2018: Treasure Island (FL).
- Santiago O, et al. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. *Eur J Clin Microbiol Infect Dis*. 2010;29(7):857–66.
- Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. *Neurology*. 1985;35(3):435–8.
- Lindsey JW, Hatfield LM, Vu T. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis. *Eur J Neurol*. 2010;17(10):1263–9.
- Sola P, et al. Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction. *J Neurol Neurosurg Psychiatry*. 1993;56(8):917–9.
- Virtanen JO, et al. Evidence for human herpesvirus 6 variant a antibodies in multiple sclerosis: diagnostic and therapeutic implications. *J Neuro-Oncol*. 2007;13(4):347–52.
- Edwards S, et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 1998;64(6):736–41.
- Brust JCM. Current diagnosis & treatment in neurology. *Lange medical book*. New York: Lange Medical Books/McGraw-Hill; 2006. p. 601.
- Jakimovski D, et al. Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. *Neurodegener Dis Manag*. 2019;9(3):149–72.
- Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. *Nat Rev Neurol*. 2017;13(1):25–36.
- Karampoor S, et al. Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: a population-based study. *J Neuroimmunol*. 2017;309:4–6.
- Manouchehrinia A, et al. Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. *J Neuro-Oncol*. 2017;23(6):839–44.

38. Rodriguez-Violante M, et al. Association of a history of varicella virus infection with multiple sclerosis. *Clin Neurol Neurosurg.* 2009;111(1):54–6.
39. Tarrats R, et al. Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. *Acta Neurol Scand.* 2002;105(2):88–94.
40. Perez-Cesari C, Saniger MM, Sotelo J. Frequent association of multiple sclerosis with varicella and zoster. *Acta Neurol Scand.* 2005;112(6):417–9.
41. Aramideh Khouy R, et al. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod. *J Neuroimmunol.* 2019; 328:94–7.
42. Sotelo J, Ordonez G, Pineda B. Varicella-zoster virus at relapses of multiple sclerosis. *J Neurol.* 2007;254(4):493–500.
43. Sotelo J, et al. The participation of varicella zoster virus in relapses of multiple sclerosis. *Clin Neurol Neurosurg.* 2014;119:44–8.
44. Ordonez G, et al. Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. *Arch Neurol.* 2004;61(4):529–32.
45. Sotelo J, et al. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. *Ann Neurol.* 2008;63(3):303–11.
46. Ordonez G, et al. Varicella zoster virus in progressive forms of multiple sclerosis. *Clin Neurol Neurosurg.* 2010;112(8):653–7.
47. Hernandez-Gonzalez O, et al. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis is infective in vitro. *Arch Med Res.* 2018;49(5): 350–5.
48. Gershon M, Gershon A. Varicella-Zoster Virus and the Enteric Nervous System. *J Infect Dis.* 2018;218(suppl_2):S113–9.
49. Kakalacheva K, Munz C, Lunemann JD. Viral triggers of multiple sclerosis. *Biochim Biophys Acta.* 2011;1812(2):132–40.
50. Kattimani Y, Veerappa AM. Complex interaction between mutant HNRNPA1 and gE of varicella zoster virus in pathogenesis of multiple sclerosis. *Autoimmunity.* 2018;51(4):147–51.
51. Munger KL, et al. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. *Mult Scler.* 2011;17(10):1185–93.
52. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. *Ann Neurol.* 2007;61(4):288–99.
53. Hedstrom AK, et al. High levels of Epstein-Barr virus nuclear Antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. *Front Neurol.* 2019;10: 1368.
54. Smatti MK, et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. *PLoS One.* 2017;12(12):e0189033.
55. Sharifipour S, Davoodi Rad K. Seroprevalence of Epstein-Barr virus among children and adults in Tehran, Iran. *New Microbes New Infect.* 2020;34: 100641.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

